Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Synaffix inks commercial license deal with ADC
December 2016
SHARING OPTIONS:

AMSTERDAM, the Netherlands—Late October saw Synaffix BV announce it had entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect and HydraSpace site-specific antibody-drug conjugate technologies.
 
Under the terms of the agreement, ADC Therapeutics has been granted a single-target license for one of its preclinical programs and has also been granted an option to take a limited number of additional single-target licenses for potential future programs. 
 
“We are delighted that ADC Therapeutics has recognized the value of our proprietary antibody-drug conjugate technologies and has elected to incorporate Synaffix technology into one of its preclinical programs,” said Floris van Delft, chief scientific officer at Synaffix. “The experience of Synaffix and its partners has consistently confirmed that, in preclinical models, our proprietary GlycoConnect and HydraSpace technologies significantly improved both efficacy and safety as compared to other mainstream site-specific conjugation approaches.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.